NEUROPHARMACOLOGY | 卷:179 |
Chronic risperidone administration leads to greater amphetamine-induced conditioned place preference | |
Article | |
Bardgett, Mark E.1  Downnen, Tyler1  Crane, Casey1  Thompson, Emily C. Baltes1  Muncie, Brittany1  Steffen, Sara A.1  Yates, Justin R.1  Pauly, James R.2  | |
[1] Northern Kentucky Univ, Dept Psychol Sci, Highland Hts, KY 41076 USA | |
[2] Univ Kentucky, Coll Pharm, Dept Pharmaceut Sci, Lexington, KY 40508 USA | |
关键词: Antipsychotic; Dopamine; Dopamine transporter; Adolescence; Development; Reinforcement; Psychostimulant; | |
DOI : 10.1016/j.neuropharm.2020.108276 | |
来源: Elsevier | |
【 摘 要 】
Risperidone is an atypical antipsychotic drug used increasingly in children to manage symptoms of ADHD and conduct disorder. In rats, developmental risperidone administration is accompanied by increased locomotor activity during adulthood, as well as heightened sensitivity to the locomotor stimulating effects of amphetamine. This study compared sensitivity to the rewarding effects of amphetamine, as measured by conditioned place preference (CPP), between groups of rats administered chronic risperidone (3.0 mg/kg, s.c.) during development (postnatal days 14-42) or adulthood (postnatal days 77-105). Locomotor activity in a novel test cage and amphetamine-induced CPP were measured beginning three and four weeks, respectively, after the final risperidone injection. Female rats administered risperidone early in life were more active than any other group tested. Previous risperidone administration enhanced amphetamine CPP regardless of sex, and this effect appeared more prominent in the developmentally treated group. The density of forebrain dopamine transporters, a primary target of amphetamine, was also quantified in rats administered risperidone early in life and found to be reduced in the medial anterior, posterior, and ventral caudate nucleus. These results suggest that chronic risperidone treatment modifies later locomotor activity and sensitivity to the reinforcing effects of amphetamine, perhaps via a mechanism related to decreased forebrain dopamine transporter density.
【 授权许可】
Free
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
10_1016_j_neuropharm_2020_108276.pdf | 2459KB | download |